Renal denervation in treatment-resistant hypertension: a reappraisal by Persu, Alexandre et al.
Renal denervation in treatment-resistant hypertension:
a reappraisal
Alexandre Persu1,2, Yu Jin3, Fadl Elmula M Fadl Elmula4,5,
Jean Renkin1,2, Aud Høieggen6, Sverre E Kjeldsen5
and Jan A Staessen3,7
Available online at www.sciencedirect.com
ScienceDirectThe Symplicity HTN-1 and 2 studies proposed renal denervation
(RDN) as an effective and safe approach to treat patients with
resistant hypertension, and were followed by an unprecedented
wave of enthusiasm. The announcement that Symplicity HTN-3
failed to meet its primary efficacy endpoint put an abrupt stop to
these overoptimistic expectations. The use of a sound
methodology was enough to see the typical 25–30 mmHg
systolic blood pressure decrease observed after RDN melt down
to <3 mmHg. RDN certainly deserves further investigation but is
not ready for wide clinical application. For the time being,
physicians should focus on improvement of drug adherence and
skilful drug treatment adjustment, which allow reaching blood
pressure target in the large majority of hypertensive patients.
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Renal denervation before Symplicity HTN-3
In 2009, Krum and colleagues [1] published a nonrandom-
ised proof-of-concept study, testing percutaneous radio-
frequency catheter-based renal sympathetic denervationCurrent Opinion in Pharmacology 2015, 21:48–52 (RDN) as a novel treatment of resistant hypertension in a
cohort of 45 patients. RDN proved feasible, effective
(blood pressure decrease: 27/17 mmHg at 12 months)
and safe. One year later, the Symplicity HTN-2 investi-
gators confirmed these impressive results in an open-label
randomized trial including 106 patients with resistant
hypertension. One hundred patients were assessed for
the primary endpoint at 6 months: in the RDN group
(n = 49), office blood pressure decreased by 32/12 mmHg
(P < 0.0001), whereas blood pressure (BP) remained
unchanged in the control group (n = 51) (+1/0 mmHg,
P  0.77). Accordingly, at 6 months the between-group
difference in office blood pressure averaged 33/11 mmHg
(P < 0.0001) [2]. There were no serious procedure-related
or device-related complications and occurrence of adverse
events did not differ between groups [2]. Similar blood
pressure decreases were documented in the Symplicity
HTN-1 registry [3] (25/11) mmHg.
Publication of the Symplicity studies [1–3] was followed
by an unprecedented wave of enthusiasm. Medtronic
Inc1 (Minneapolis, Minnesota, USA) paid $800 million
up front to purchase Ardian1 (Mountain View, California,
USA), the company that had developed the technology
[4]. More than ten companies developed their own RDN
system, five of which obtained the CE mark. While RDN
remained an investigational procedure in the US, 8000,
possibly 15 000–20 000 procedures were performed in
Europe in less than 4 years [5], most of them using the
mono-electrode Ardian-Medtronic1 catheter. Campaigns
(www.poweroverpressure.com) and editorials [6] empha-
sising the high prevalence and major cardiovascular bur-
den associated with resistant hypertension, and the
urgent need for alternative, non-drug approaches flour-
ished. New papers devoted to RDN were published every
week, and all top-ranking journals were keen to publish
studies and reviews addressing this novel approach [4]. In
the meantime, dissenting and cautionary advice [7,8] and
predictions [9] remained almost unheard.
Symplicity HTN-3
Symplicity HTN-3 [10] — a US randomized controlled
trial including 535 patients assigned in a 2:1 ratio to RDN
or a sham procedure put a stop to overoptimistic expec-
tations. In contrast with Symplicity HTN-2 [2], in Sym-
plicity HTN-3 [10], the mean decrease in office systolic
blood pressure at 6 months was only 14.1 mm Hg in thewww.sciencedirect.com
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the sham group. In terms of baseline-adjusted between
group difference, these numbers translate into a modest
2.4 mmHg advantage in favour of the technique, lower
than the preset superiority margin of 5 mmHg [10].
Similarly, while in Symplicity HTN-2, the systolic 24-h
ambulatory blood pressure decrease was 11 mmHg in
20 patients treated with RDN (P = 0.006) compared to
a non-significant (P = 0.51) decrease of 3 mmHg in
25 patients from the control group [2], in Symplicity
HTN-3, the 24-h ambulatory blood pressure decrease
was modest and of the same order of magnitude in both
groups (6.8 and 4.8 mmHg, respectively; P < 0.001 for
both) [10] (Table 1).
Proponents of RDN attributed the disappointing results of
Symplicity HTN-3 to the lack of experience of most US
operators with the procedure, insufficient proctoring and
low average number of procedures per centre (3) [11–13].
Retrospective analyses of stored angiographic and proce-
dural records support these claims. They showed that in
74% of patients not even one fully circumferential renal
artery application was achieved and that energy delivery
was preferentially applied to the proximal artery, while
renal nerves are closer to the distal artery [13] Notably also,
the number of ablations delivered was significantly corre-
lated with office blood pressure decrease after RDN [14].
Still, this correlation did not reach statistical significance
for ambulatory blood pressure [14]. Furthermore, it should
be reminded that these analyses are all post hoc and thusTable 1
Characteristics and results of 3 prospective and randomized studies o
Variable Symplicity HTN-2 OSLO-
Year 2010 2014 
Design Open Open 
Drug adherence Patient
diary
Witnes
intake
RDN Control RDN C
No. of patients 52 54 9 10
No. of drugs 5.2 5.3 5.1 5.0
Intervention RDN No
active
RDN Dr
ad
Office SBP
Baseline, mmHg 178 178 156 16
DFU — 6 month, mmHg 32 +1 8 2
DRDN — control, mmHg 33 +20 
Ambulatory SBP
Baseline, mmHg ?* ?* 152 15
DFU — 6 month, mmHg 11 3 10 1
DRDN — control, mmHg 8** +9 
Adapted from Ref. [27]
SBP, systolic blood pressure; RDN, renal denervation; 6 month, 6-month foll
of control group. ?*, baseline ambulatory BPs values were not given in this s
renal denervation group and 25 patients in control group.
www.sciencedirect.com are no more than hypothesis-generating [14]. Finally,
technical reasons alone cannot account for the most striking
difference between Symplicity HTN-2 [2] and Symplicity
HTN-3 [10]: while in Symplicity HTN-2, blood pressure
remained unchanged in the placebo arm, in Symplicity
HTN-3 it decreased to almost the same extent as in the
RDN arm.
The most credible explanation is that Symplicity HTN-3
[10] was blinded, while other studies were randomized
but un-blinded (Symplicity HTN-2) [2] or purely obser-
vational. By contrast with Symplicity HTN-3, open-label
studies such as Symplicity HTN-2 are subject to expec-
tation, performance and evaluation biases [8]. In other
words, knowing to which treatment group participants are
allocated may have affected both physicians’ and
patients’ behaviour, particularly if they felt that RDN
was the last option available — as implied by the concept
of resistant hypertension — or strongly believed in the
efficacy of the technique. Symplicity HTN-2 investiga-
tors may have been inclined to measure blood pressure
differently in the two groups: for example, the resting
period before office BP measurements and the number of
BP measurements taken may not have been the same in
the RDN and control arms [8]. On the other side, being
in the RDN group, and as such benefitting from increased
attention from the caring physician may have improved
adherence to drug treatment [7,8,9]. Conversely,
patients from the control arm may have been tempted
not to take properly their medications in order to benefitf blood pressure lowering effects of RDN with Symplicity catheters
RDN Symplicity HTN-3 PRAGUE-15
2014 2014
SHAM single-blind Open
sed Patient diary Plasma drug
concentration
ontrol RDN Control RDN Control
 364 171 52 54
 5.1 5.2 5.1 5.4
ug
justment
RDN No
active
RDN Drug
adjustment
0 180 180 159 155
8 14.13 11.74 12.4 14.3
2.39 1.9
2 159 160 149 147
9 6.75 4.79 8.6 8.1
1.96 0.5
ow-up; DRDN-control in favour of renal denervation group; +D in favour
tudy. 8** results is given just for the difference between 20 patients in
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50 Cardiovascular and renalfrom RDN after assessment of the primary endpoint at six
months [7,8]. In contrast, in a blinded study as Symplicity
HTN-3 [10], such biases are minimized. In particular,
improved adherence to drug treatment due to inclusion of
patients in a trial and massive attention devoted to them
(Hawthorne effect) is likely to have occurred irrespective
of the treatment arm, accounting for part of the substan-
tial blood pressure decrease in the control group [15].
This phenomenon may have been particularly important,
albeit not limited to the subgroup of 25% African-Ameri-
can patients [13,14].
The key message of Symplicity HTN-3 [10] is simple:
in patients meeting the entry criteria of the study (and
probably those of Symplicity HTN-1 and 2 as well), the
true overall benefit of RDN on systolic blood pressure is
modest, <3 mmHg, without evidence of a favourable
impact on morbidity-mortality so far. The results of three
other recent rigorously executed randomized controlled
trials using the same catheter, Oslo RDN [5] (Table 1),
PRAGUE-15 [16] (Table 1) and DENER-HTN [17]
including a lower number of well-trained operators are
in line with those of Symplicity HTN-3 [10], and
confirm that the failure of RDN to achieve superiority
over medical treatment cannot be entirely explained by
inclusion of a high proportion of African Americans or
insufficient degree of renal nerve ablation. Notably, in
these studies [5,16,17], the absence of sham control group
is compensated by the use of ambulatory blood pressure
measurement both for patients’ selection and evaluation
of efficacy, associated with evaluation of adherence using
witnessed drug intake (OSLO-RDN) [5], or measure-
ment of drugs in the urine (DENER-HTN and PRA-
GUE-15) [16,17]. This nice design allows controlling
largely for both white coat and Hawthorne effects, while
avoiding exposure of patients to unnecessary procedures.
In the same line, a fourth randomized sham-controlled
study performed in mild resistant hypertension (daytime
systolic blood pressure between 135 and 149 mmHg and/
or daytime diastolic blood pressure between 90 and
94 mmHg on 3 drugs classes including a diuretic),
Symplicity Flex [18], failed to show any advantage of
RDN compared to drug treatment alone.Table 2
Previous reports of renal artery stenosis or stenosis progression follo
RDN system No. of
cases
Pre-existing
stenosis (No.)
Symplicity (Ardian-Medtronic) 19 5 
Vessix-Boston 5 3 
EnligHTN (Saint-Jude) 4 2 
Paradise (Recor, 1st generation) 2 No 
One Shot (Maya Covidien) 1 NR 
Total 31 10 
Updated from Ref. [20]
NR: not reported; PTA: percutaneous angioplasty; RDN: renal denervation
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Most expert centres have witnessed a substantial blood
pressure decrease after RDN in a minority of patients
[5,19]. However, the current inability to identify those
few responders, the modest overall benefits, and the high
cost of the intervention should be balanced with its
potential risks. In particular, more than 20 cases of de
novo renal artery stenosis have been reported after RDN,
most of them after the announcement that Symplicity
HTN-3 failed to meet its primary endpoint [20–22]
(Table 2). In view of these results, previous pharmaco-
economic [23–25] analyses became irrelevant, because
they were based on weak assumptions. RDN deserves
further investigation but is not ready for clinical use and
should be restricted to research protocols [26]. Accord-
ingly, in Germany, the insurances companies which were
the first in Europe to reimburse the procedure have
terminated their coverage [27] and even well-known
proponents of the technique acknowledge that RDN
‘should be returned back to the academic arena’ [28]
before further clinical deployment. Lessons learnt from
RDN should also be applied for other new treatment
approaches of resistant hypertension such as electrical
stimulation of baroreceptors [29] or creation of arteriove-
nous anastomosis [30]. Rather than wasting energy and
money in numerous observational studies, such therapies
should be evaluated in properly designed randomized
controlled trials using a rigorous methodology. Further-
more, especially in the initial phase, these techniques
should be reserved to truly resistant hypertensive
patients, after careful exclusion of patients with second-
ary or white-coat resistant hypertension, and poorly
adherent patients.
Are this news really bad news? Not really. After publica-
tion of Symplicity HTN-2, physicians and the lay public
were too often swamped by an aggressive marketing
emphasising not only the safety and efficacy of RDN,
but also the alleged huge unmet need in the management
of resistant hypertension and urgency of novel, non-
drug treatment approaches. Critical analyses of the liter-
ature and recent studies show that these claims were
largely exaggerated. The estimated 20–30% prevalencewing renal denervation
Time after
RDN (months)
Bilateral/multiple
stenosis (No.)
PTA/stenting
(No.)
6 (median) 4 14
3–12 1 1
3–9 1 2
6 NR 1
6 NR –
3–12 6 18
.
www.sciencedirect.com
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come trials [31] may be grossly overinflated due to inclu-
sion of a substantial proportion of patients in whom drug
treatment was not properly uptitrated [32]. Apparent
treatment-resistant hypertension — that is uncontrolled
office blood pressure on 3 or more antihypertensive drugs
including a diuretic or blood pressure controlled on
4 drugs or more — accounts for 8.9% of the US adult
hypertensive population and 12.9% in the subset receiv-
ing antihypertensive drugs [33]. However, this subset also
includes an unknown proportion of patients with second-
ary and white coat hypertension and poorly adherent
patients. In the 2010–2011 database of a large Israeli
healthcare organisation [34], resistant hypertensive
patients defined as uncontrolled patients despite adher-
ence to a drug regimen including a diuretic and at least
2 other antihypertensive drug classes at their maximal
recommended dose accounted for only 2.2% of uncon-
trolled hypertensive patients and <1% of the total study
population. This proportion may still be an overestimate,
as screening for secondary or white coat resistant hyper-
tension was performed only in a small minority of patients
[34]. Along the same lines, in a single centre retrospec-
tive chart review, the proportion of patients with resistant
hypertension decreased from 30.9% to 3.4% when triple
therapy had to include maximally dosed medications
including a diuretic [35]. Finally, drug dosages in urine
or plasma of patients with resistant and difficult-to-treat
hypertension documented poor or non-adherence in
23.5–65.5% of patients [36,37,38,39].
In conclusion, patients with uncontrolled office blood
pressure despite a triple therapy at maximal dose including
a diuretic probably represent less than 5% of hypertensive
patients. The prevalence of truly resistant hypertension,
after exclusion of white coat and secondary hypertension,
and apparently resistant hypertension due to low drug
adherence may still be one order of magnitude lower. Even
in this limited subset, blood pressure control may be
achieved in a substantial proportion of patients by skilful
drug treatment adjustment in expert centres [5,40]. While
RDN deserves more in depth research, in the present
state of knowledge, initiatives aiming at diagnosing and
improving poor drug adherence [5] and optimisation of
drug treatment [5,38] may prove much more cost-effective,
both at the individual and public health policy level.
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